Publications by authors named "Jan Hamouz"

Claim this Profile
R
Reply.
Scott Friedman, Nikolas London, Jan Hamouz, Ágnes Kerényi, Andras Papp

Ophthalmol Retina· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration.
Scott Friedman, Nikolas London, Jan Hamouz, Ágnes Kerényi, Andras Papp

Ophthalmol Retina· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration: A Phase III Randomized Trial.
Jan Hamouz, Agnieszka Nowosielska, Anna Święch-Zubilewicz, Santiago Abengoechea, Kristine Baumane

Ophthalmol Retina· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
Neil M Bressler, Miroslav Veith, Jan Hamouz, Jan Ernest, Dominik Zalewski

Br J Ophthalmol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Se Joon Woo, Miroslav Veith, Jan Hamouz, Jan Ernest, Dominik Zalewski

JAMA Ophthalmol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis